Gilead Sciences | GILD - Pre Tax Profit


Gilead Sciences reported $2.08B in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
ALKERMES USD -61.93M 122.3M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Coherus Biosciences USD -46.35M 90.86M Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Glaxosmithkline GBP 2.46B 569M Sep/2025
Incyte USD 343.6M 46.34M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Moderna USD -799M 612M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novartis USD 3.84B 802M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
United Therapeutics USD 444M 6M Dec/2025
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026